Mereo BioPharma Group plc - ADR (MREO)
Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Mereo BioPharma: Buy Rating Despite No Early Study Completion Of Setrusumab For OI
Mereo BioPharma Group plc's phase 3 ORBIT study for setrusumab in osteogenesis imperfecta will continue to final analysis, expected by end of 2025. The recent 35% MREO stock drop was due to not meeting early efficacy stopping criteria of ORBIT, not due to safety or trial failure. The ongoing phase 2/3 ORBIT study is targeting OI patients ages 5 to 25, while the phase 3 COSMIC trial is going after patients ages 2 to < 7 years.
MEREO BIOPHARMA (MREO) Upgraded to Buy: What Does It Mean for the Stock?
MEREO BIOPHARMA (MREO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Mereo BioPharma: Setrusumab Chugs Along With Possible Inflection Points
Mereo BioPharma Group plc's setrusumab shows promise in treating osteogenesis imperfecta, with phase 3 studies fully enrolled and potential for multiple catalysts in 2025. Positive 14-month data from the phase 2/3 ORBIT study indicates a significant reduction in fracture rates, bolstering confidence in ongoing phase 3 trials. Financially stable with $87.4 million in cash, Mereo aims to secure a partner for Alvelestat's phase 3 trial, potentially boosting stock value.
Equities Analysts Offer Predictions for Mereo BioPharma Group plc’s Q2 2024 Earnings (NASDAQ:MREO)
Mereo BioPharma Group plc (NASDAQ:MREO – Free Report) – Equities researchers at Leerink Partnrs issued their Q2 2024 earnings per share estimates for shares of Mereo BioPharma Group in a report released on Wednesday, May 15th. Leerink Partnrs analyst J. Schwartz forecasts that the company will earn ($0.01) per share for the quarter. The consensus estimate for Mereo BioPharma Group’s current full-year earnings is $0.03 per share. Leerink Partnrs also issued estimates for Mereo BioPharma Group’s Q3 2024 earnings at ($0.01) EPS, Q4 2024 earnings at $0.16 EPS and FY2025 earnings at $0.03 EPS. MREO has been the subject of a number of other research reports. Cantor Fitzgerald restated an “overweight” rating and set a $7.00 price objective on shares of Mereo BioPharma Group in a research report on Thursday. Needham & Company LLC restated a “buy” rating and set a $6.00 price objective on shares of Mereo BioPharma Group in a research report on Thursday. Get Our Latest Report on Mereo BioPharma Group Mereo BioPharma Group Stock Performance Shares of Mereo BioPharma Group stock opened at $3.20 on Monday. The business has a 50-day moving average price of $3.04 and a 200-day moving average price of $2.90. The company has a debt-to-equity ratio of 0.09, a quick ratio of 6.72 and a current ratio of 6.72. Mereo BioPharma Group has a twelve month low of $0.92 and a twelve month high of $4.36. Institutional Trading of Mereo BioPharma Group Institutional investors have recently added to or reduced their stakes in the company. Advisors Preferred LLC bought a new stake in Mereo BioPharma Group in the first quarter worth about $28,000. SG Americas Securities LLC bought a new stake in Mereo BioPharma Group in the first quarter worth about $54,000. BNP Paribas Financial Markets lifted its stake in Mereo BioPharma Group by 581,066.7% in the first quarter. BNP Paribas Financial Markets now owns 17,435 shares of the company’s stock worth $58,000 after purchasing an additional 17,432 shares during the last quarter. Golden State Equity Partners lifted its stake in Mereo BioPharma Group by 41.0% in the fourth quarter. Golden State Equity Partners now owns 20,300 shares of the company’s stock worth $47,000 after purchasing an additional 5,900 shares during the last quarter. Finally, Index Fund Advisors Inc. bought a new stake in Mereo BioPharma Group in the first quarter worth about $99,000. Institutional investors own 62.83% of the company’s stock. About Mereo BioPharma Group (Get Free Report) Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors.
